Terumo (4543) Investor presentation summary

Agreement decision

• Agreed to terminate the CSL Plasma supply agreement effective Oct. 8, 2026, and implement a transition plan for an orderly wind-down of supply activities.

• CSL Plasma notified TBCT in Aug. 2026 that it would transition part of its collection centers to another technology platform, citing areas where Rika did not fully meet customer expectations.

• After reassessing long-term outlook, required investment and expected returns, TBCT will focus resources on businesses with larger market opportunities and stronger profitability.

Financial impact and FY26 guidance

• FY26 estimated impairment charges of US$450M, primarily for manufacturing facilities, equipment and other fixed assets; non-cash.

• FY26 estimated related costs of US$160M for transition-period business losses, contract termination, restructuring and employee-related costs; estimates may change with future developments.

• FY26 guidance, in ¥100M: sales 12,390 to 12,295; AOP 2,745 (22.2%) unchanged; OP 2,575 (20.8%) to 1,600 (13.0%); net profit 1,931 to 1,200; dividend/share ¥36 unchanged.

Plasma Innovations business assessment

• Plasma Innovations is reported within TBCT, with CSL Plasma its primary customer and source of the vast majority of PI revenue; strategic collaboration began in 2021.

• Rika received U.S. FDA clearance in 2022; a Colorado disposables manufacturing facility was established, with approximately US$250M invested in the business.

• Broader customer needs—including reliability, ease of use, software, connectivity and operational support—required more investment and time; volume growth and profitability improvement were delayed by more than two years.